Moving from promise to practice
CEO of the Adelphi Group, and meeting chairman
Modern medicine and the drug development process have long been directed by the law of averages — aimed at greatest effect across the largest number of patients. Yet this assumption is flawed in terms of outcomes for the individual patient and wasteful at the economic level. In recent years, scientific breakthrough has led to exciting developments in diagnostics and biomarkers, allowing clearer identification of differences in genotype, patho-physiology and treatment response, and paving the way for more targeted approaches.
In this meeting, designed for senior pharmaceutical executives across disciplines, Stuart Cooper challenged delegates to ask themselves...
"Is it all about new science, or is there more
to the Personalised Medicine story?"